Grifols 관리

관리 기준 확인 2/4

Grifols CEO는 Nacho Abia Buenache, Apr2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 € 942.54K 가치에 해당하는 회사 주식의 0.014% 직접 소유합니다. 942.54K. 경영진과 이사회의 평균 재임 기간은 각각 6.8 년과 7 년입니다.

주요 정보

Nacho Abia Buenache

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.01%
경영진 평균 재임 기간	6.8yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

Recent updates

CEO

Nacho Abia Buenache (56 yo)

less than a year

테뉴어

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jose Ignacio Abia Buenache	CEO & Director	less than a year	데이터 없음	0.014% € 942.5k
Alfredo Guerra	CFO & VP	17.8yrs	데이터 없음	데이터 없음
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	데이터 없음	데이터 없음
Nuria Lapeña	VP of Corporate Treasury	no data	데이터 없음	데이터 없음
David Bell	Chief Corporate Development	21.8yrs	데이터 없음	0.0029% € 202.9k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.8yrs	데이터 없음	0.00078% € 53.8k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	데이터 없음	데이터 없음
Vicente Blanquer Torre	Chief Quality Officer	31.8yrs	데이터 없음	데이터 없음
Sergio Adell	President of Commercial Tech Support	5.8yrs	데이터 없음	데이터 없음
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% € 1.1m
Miguel Montblanch	President of Commercial Operations Support	12.8yrs	데이터 없음	데이터 없음
Daniel Coit	Chief Industrial Services Officer	5.8yrs	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: G0F0 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jose Ignacio Abia Buenache	CEO & Director	less than a year	데이터 없음	0.014% € 942.5k
Víctor Grifols Deu	Executive Director	8.5yrs	€1.04m	0.016% € 1.1m
Iñigo Mardones	Independent Director	9.5yrs	€150.00k	데이터 없음
Thomas Glanzmann	Non-Executive Chairman	18.6yrs	€1.90m	0.029% € 2.0m
Juan Twose Roura	Member of the Advisory Committee	9.8yrs	€380.00k	데이터 없음
Raimon Grifols Roura	Vice-Chairman	9.5yrs	€1.04m	0.0060% € 417.4k
Tomas Daga Gelabert	Independent External Director	24.6yrs	데이터 없음	0.045% € 3.1m
Albert Coma-Cros	Proprietary Director	less than a year	데이터 없음	0.0097% € 670.0k
Enriqueta Font	Independent Director	5.5yrs	€125.00k	데이터 없음
Montserrat Abellana	Lead Independent Director	2.4yrs	€63.00k	데이터 없음
Susana Gonzalez Rodriguez	Independent Director	2.4yrs	€63.00k	데이터 없음
Anne-Catherine Berner	Independent Director	less than a year	데이터 없음	데이터 없음

7.0yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: G0F0 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Grifols 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령